Abstract Secondary polycythemia, a disease characterized by a selective increase in circulating mature erythrocytes, is caused by enhanced erythropoietin (Epo) concentrations triggered by hypoxia-inducible factor-2α (HIF-2α). While mechanisms of hypoxia-dependent stabilization of HIF-2α protein are well established, data regarding oxygen-independent regulation of HIF-2α are sparse. In this study, we generated a novel transgenic mouse model, in which biglycan was constitutively overexpressed and secreted by hepatocytes (BGN Tg
Introduction
Polycythemia is a disease characterized by an increased number of mature erythrocytes in the circulation causing enhanced blood viscosity and thereby augmenting the clinical risk of thrombosis, cardiac infarction and stroke [1, 2] . Primary polycythemia (polycythemia rubra vera or Vaquez' disease) is a chronic myeloproliferative disorder of the bone marrow marked by enhanced number of erythrocytes, leukocytes and thrombocytes and low levels of erythropoietin (Epo). In contrast, secondary polycythemia, frequently induced by hypoxic conditions such as heavy smoking, chronic obstructive pulmonary diseases and living at high altitude, is caused by enhanced Epo concentrations with selective increase of the erythrocyte number [3] . Epo, a protein of 30 kDa, is in adults mainly produced in the kidney by interstitial cells and to some degree in the liver by hepatocytes [4] [5] [6] . Epo is a crucial regulator of erythropoiesis that stimulates the proliferation and terminal differentiation of erythroid precursor cells [4, 7] . Therefore, administration of recombinant Epo has become the standard treatment for anemia in chronic kidney disease [8] .
The transcription of the Epo gene is tightly regulated by various oxygen-sensing mechanisms [8, 9] . A key hypoxiainducible transcription factor that regulates Epo production is the so-called Endothelial PAS domain-containing protein 1 (EPAS1), also known as hypoxia-inducible factor-2α (HIF-2α) [10] . Mutations in EPAS1 genes cause erythrocytosis familial type 4 [11] and are associated with pulmonary hypertension and chronic mountain sickness [12] . Under physiological (non-hypoxic) conditions, HIF-2α is unstable due to hydroxylation of its α-subunit by prolyl hydroxylase domain proteins (PHDs), resulting in ubiquitination and degradation [10] . By contrast, upon hypoxia PHD-mediated posttranslational modification of HIF-2α is inhibited, leading to its stabilization and subsequent transcription of HIF-2α target genes [13] . Besides hypoxia, nitric oxide (NO), reactive oxygen species (ROS), succinate, fumarate, cobalt chloride and iron chelators have been shown to protect HIF-2α from degradation, resulting in increased Epo expression [8, 14] . In turn, several growth factors, tumor suppressors and oncogenes have been shown to stabilize HIF-1α [15] . Taken account that HIF-2α is crucial in Epo production, it is surprising that data regarding oxygenindependent regulation of HIF-2α are rather sparse.
There is growing evidence that components of the extracellular matrix (ECM) have not only a structural function within the ECM but may also act in their soluble form as signaling molecules [16, 17] . Biglycan, a class I small leucine-rich proteoglycan [16] , is proteolytically released from the ECM upon tissue stress or injury as a soluble molecule thereby acting as a danger signal [18] [19] [20] [21] . As an endogenous ligand of the innate immune receptors such as Toll-like receptor (TLR)-2 and -4 [20] [21] [22] [23] , soluble biglycan promotes inflammation via its ability to evoke the expression of proinflammatory cytokines and chemokines [22, [24] [25] [26] . We have previously established that transient overexpression of soluble biglycan in mice exerts profound pro-inflammatory effects and provided a direct in vivo proof for biglycan signaling via TLR2/4 [25] [26] [27] . Moreover, we have shown in the same mouse model that soluble biglycan can differentially target either one of the TLRs or its associated adaptor molecules, thereby regulating the inflammatory response and disease outcome [26] [27] [28] . It is now well accepted that circulating biglycan levels correlate with organ dysfunction in sterile and pathogen-induced inflammation [19] . However, the in vivo consequences of a chronic exposure to soluble biglycan have not been investigated yet.
In this study, we generated a mouse line stably overexpressing soluble human biglycan (BGN   Tg   ) . Surprisingly, BGN Tg mice exhibited markedly enhanced Epo levels that were associated with higher HIF-2α levels and increased erythrocyte numbers. We found that this novel biological activity of biglycan to induce Epo synthesis required exclusively TLR2. To the best of our knowledge, this is the first report of a soluble proteoglycan stimulating Epo synthesis and red blood cell production in vivo by enhancing HIF-2α levels in the liver and kidney.
Materials and methods

Animal experiments
C57BL/6J mice (referred to as BWT^) were purchased from Jackson Laboratories (Bar Harbor, ME). [29, 30] . To overexpress biglycan in liver, the 1.1-kb full-length cDNA fragment of human biglycan was inserted downstream of the XhoI/XbaI site of pGEMAlbSVPA vector containing the albumin enhancer-promoter (E/P) sequence. The 4.7 kb biglycan transgene construct was linearized by ApaI/PvuII and purified. The hBGN transgenic founders (BGN Tg ) were generated by microinjection of the linearized DNA into C57BL/6J zygotes. Potential founders were identified by genotyping PCR. Total genomic DNA was isolated from tail biopsies by KAPA Mouse Genotyping Hot Start Kit (PEQLAB, Germany) and subjected to PCR with primers binding within the albumin E/P sequence and hBGN cDNA sequence, yielding a band of 410 bp. The following primer pair was used: 5′-CTG CAC ACA CGA TCA CCT TT-3′ and 5′-TTG TTG TTC ACC AGG ACG AG-3′. The BGN Tg founders were then backcrossed to C57BL/6J mice for more than 30 generations to evaluate breeding potential and transgene transmissibility. No special feeding or breeding procedures have been used. 8-12 weeks old male mice were used for experiments. All animal work was conducted in accordance with the German Animal Protection Law and was approved by the Ethics Review Committee for Laboratory Animals of the District Government of Darmstadt, Germany.
Hematological screening
Thirty WT and BGN Tg mice, with 15 male and 15 female each, all born within 1 week, were shipped to the German Mouse Clinic (GMC) for hematological analysis. At the GMC, mice were kept in IVC cages with water and standard mouse chow (Altromin no. 1314) according to the GMC housing conditions and German laws. Blood samples were collected from isoflurane-anesthetized mice by retro-bulbar puncture using a glass capillary (0.8 mm outer diameter). About 50 μl was collected in an EDTA-coated end-to-end capillary and diluted 1:5 with cell pack buffer (Sysmex Capillary tube, Sysmex Deutschland, Norderstedt, Germany) for hematological analysis. An additional aliquot of blood was collected in a Li-heparin coated sample tube (Kabe Labortechnik, Nümbrecht-Elsenroth, Germany) for clinical chemistry measurements. Diluted EDTA blood samples were analyzed using a Sysmex XT200iV blood cell counter to determine erythrocyte count, hemoglobin concentration as well as calculated hematocrit [31] . Heparin-blood samples were stored at room temperature for up to 2 h before being separated by centrifugation with 5000 x g for 10 min at 8°C (Biofuge fresco, Heraeus, Germany). Plasma was transferred to 1.5 ml Eppendorf tubes, diluted 1:2 with deionized water and analyzed for a standard set of 20 clinical chemistry parameters including iron and unsaturated iron binding capacity by applying test kits provided by Beckman-Coulter using an AU480 auto-analyzer (Beckman-Coulter Germany, Krefeld, Germany) as described previously [32] . Total iron binding capacity was calculated as the sum of iron concentration and unsaturated iron binding capacity. All tests performed at the GMC were approved by the responsible authority of the Government of Upper Bavaria, Germany. For erythrocyte count from mice transiently overexpressing biglycan, 50 μl of heparinized blood was diluted 1:10,000 in PBS and erythrocytes counted in a counting chamber under the microscope. The counting was performed by 2 independent scientists blinded to the conditions.
Real-time quantitative polymerase chain reaction
Total RNA was extracted from kidneys and liver using the TRIreagent (Sigma Aldrich, Heidelberg, Germany) as described [33] . cDNA was reverse transcribed using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Germany). Real-time quantitative PCR was performed using AbiPrism 7500 Sequence Detection System and Luminaris High Green Low ROX qPCR Mastermix (Thermo Fisher Scientific, Germany) with the following primer pairs: human/mouse BGN, 5′-CTA CAT CTC CAA GAA CCA CCT G-3′ and 5′-ATG CAG TTC ATG TTC CGG AG-3′; mouse Epo, 5′-CTC AGA AGG AAT TGA TGT CG-3′ and 5′-AGT TGG CGT AGA CCC GGA AG-3′ and mouse Gapdh, 5′-CAT GGC CTT CCG TGT TCC TA-3′ and 5′-CCT GCT TCA CCA CCT TCT TGA T-3′. Relative changes in gene expression compared to control and normalized to Gapdh were quantified by the 2 -ΔΔCt method. For semi-quantitative RT-PCR the 5× Mastermix Bready to use^(Bio&Sell, Feucht, Germany) and the following primer pair were used: murine Bgn, 5′-AAC AAC CCT GTG CCC TAC TG-3′ and 5′-GCT TAG GAG TCA GGG GGA AG-3′; amplifying a band of 222 bp and human/murine BGN, 5′-TGG AGA ACA GTG GCT TTG AA-3′ and 5′-TGT TGA AGA GGC TGA TGC-3′, yielding a band of 428 bp. Only the product from hBGN transgene can be digested by SacI to 268 and 160 bp.
Isolation and semi-quantification of biglycan from tissues and plasma
Biglycan from the kidney and liver homogenates as well as plasma samples (n = 3 for each group) was extracted and semi-purified as described previously [25, 33] . The glycosaminoglycan chains of the proteoglycan were then digested with chondroitinase ABC (Seikagaku Corporation, Tokyo, Japan) and the protein was subjected to polyacrylamide gel electrophoresis followed by Western blot analysis with subsequent quantification as described previously [25, 33] . A known amount of intact biglycan (containing protein core and glycosaminoglycan chains) was used as positive control for validation [33] . Purification and digestion with chondroitinase ABC of all samples was performed in parallel and under the same conditions. Renal and hepatic biglycan content was calculated per mg protein of organ homogenates used for proteoglycan isolation. Approximately 150 mg of kidney and liver and 200 μl of plasma were used for the isolation. The results of three isolations per group were averaged.
Western blot and ELISA
Epo protein concentration in organ lysates and plasma was measured by a mouse specific ELISA (BioLegend, London, UK) according to the manufacturer's instructions. For Western blot analysis, kidney and liver samples were homogenized and sonicated in lysis buffer containing 137 mM NaCl, 20 mM Tris/HCl, pH 8.0, 5 mM EDTA, 10 % glycerol, 1 % Triton X-100, centrifuged at 4°C at 13,000 rpm for 15 min and supernatants were snap-frozen and stored at −80°C. Western blots were performed and quantified as described [33] using the following primary antibodies: goat anti-biglycan (TA302434, Acris Antibodies), mouse anti-β-Actin (A5441, Sigma Aldrich) and rabbit anti-mouse HIF-2α (NB100-122, Novus Biologicals). Secondary antibodies were rabbit anti-goat (H + L, Jackson ImmunoResearch), HRP-coupled donkey anti-rabbit (NA934V, GE Healthcare) and HRP-coupled sheep anti-mouse (NA931V, GE Healthcare). Signal detection was performed using the ECL Western blotting detection system (GE Healthcare, Freiburg, Germany) and optical density of bands was obtained using Scion Image Software (Scion Corporation).
Histopathology
For visualizing general structure of the tissue, periodic acidSchiff (PAS) staining was performed. Sections (4 μm) of paraffin-embedded spleens from mice were deparaffinized and immersed in periodic acid solution (Applichem, Germany) for 10 min and further in Schiff's solution (Carl Roth, Germany) for 20 m in after proper w ash. Counterstaining was performed with Mayer's Hematoxylin (Sigma Aldrich, Germany). Quantification of red pulp (RP) and white pulp (WP) surface area was carried out using Scion Image Software. RP and WP surface area was measured across the entire surface area of the central longitudinal spleen section, the RP/WP ratio and the percentage of RP was then calculated.
For Perls' Prussian blue staining, deparaffinized tissue sections were immersed in the mixed solution of 10 % potassium ferrocyanide (Applichem, Germany) and 20 % hydrochloric acid (Sigma Aldrich, Germany) for 20 min. Counterstaining was proceeded with Nuclear fast red (Sigma Aldrich, Germany). At least 10 high-power fields (magnification, ×10) per section for each sample were examined. Perls' Prussian blue staining was quantified by determination of chromogen intensity using software ImageJ-Fiji version. Histological examinations were performed by 2 pathologists blinded to the conditions.
Transient overexpression of soluble biglycan in vivo
To generate mice transiently overexpressing soluble biglycan, human biglycan cDNA (hBGN) was inserted into the BamHI/ SacII site of the pLIVE™ (Liver In Vivo Expression) vector containing the mouse albumin promoter (Mirus Bio, Madison, USA) [26, 27] . Human biglycan was expressed in male mice by a single intravenous injection of the hBGN pLIVE vector (50 μg) in 400 μl of 5 % glucose and 6 μl of TurboFect In Vivo Transfection Reagent (Thermo Fisher Scientific, Schwerte, Germany) under 2 % isofluorane (Abbott laboratories, Wiesbaden, Germany) and 1 l/min oxygen anesthesia. For controls, empty pLIVE vector was used (pLIVE). Mice were sacrificed for collection of blood and organs 3-days after injection.
Statistics
All data are expressed as means ± S.D. Two-sided Student's t test was used to evaluate significance of differences between groups. Differences were considered significant with P < 0.05. Note that P-values are not corrected for multiple testing. In box plots single values are presented with 10th and 90th percentile whiskers. Each data point outside the 10th and 90th percentiles is plotted.
Results
Generation of mice stably overexpressing soluble biglycan
To address the clinical consequences of chronically-enhanced plasma levels of soluble biglycan, we generated a mouse line stably overexpressing human biglycan (BGN Tg ) exclusively in the liver. Analogous to our mouse model of transient overexpression of soluble biglycan [25, 27] , we expected that hepatocytes would release this proteoglycan into the circulation where it would target various organs via ligand-receptor interactions. To this end, we cloned the full-length human biglycan cDNA downstream of the albumin promoter (Fig. 1a) to ensure organ-specific and continuous overexpression of the transgene by hepatocytes. The construct was then introduced into fertilized pronuclei of C57BL/6J mice where it was inserted into the genomic DNA by homologous recombination. The resulting mice overexpressing human biglycan were identified by genotyping (Fig. 1b) and crossed to obtain homozygosity. qRT-PCR with primers detecting both murine and human biglycan verified an 18-fold increase in biglycan mRNA expression in liver of BGN Tg mice compared to agematched (8 weeks-old) wild-type (WT) littermates (Fig. 1c) . Semi-quantitative RT-PCR with primers specific for murine biglycan demonstrated no difference in the expression of endogenous biglycan in the liver of WT and BGN Tg mice (Fig. 1d) . cDNA isolated from human embryonic kidney (HEK) cells stably overexpressing human biglycan was used as negative control to verify the specificity. Human and murine biglycan genes share a 90 % homology; however, benefiting from an additional SacI restriction site on human biglycan cDNA, we designed a PCR to distinguish the transgene from the endogenous transcriptions. With SacI digestion, we confirmed that the increase in biglycan mRNA expression (Fig. 1c) was due to the overexpression of the human transgene whereas the endogenous mRNA remained unchanged (Fig. 1e) . Elevated biglycan mRNA expression resulted in a 3-fold increase of biglycan protein in the liver (WT 0.54 ± 0.30 vs. BGN Tg 1.48 ± 0.24; n = 3; P < 0.05) (Fig. 1 f) and a 2-fold increase in plas ma (WT 0.14 ± 0.04 μg/ml vs. BGN Tg 0.29 ± 0.10 μg/ml; n = 3; P < 0.05) (Fig. 1g) . This was followed by enhanced accumulation of biglycan protein in various organs, here shown for the kidney (WT 0.11 ± 0.04 vs. BGN Tg 0.76 ± 0.38; n = 3; P < 0.05) (Fig. 1f) . Similar results were obtained in 8-12 weeks-old mice. Thus, these data demonstrate an overexpression of human biglycan in the liver, followed by elevated levels of circulating biglycan with subsequent enhanced renal accumulation of this proteoglycan.
BGN
Tg mice develop polycythemia BGN Tg mice displayed no obvious phenotype, as the mice had normal growth, weight, lifespan and fertility. However, a hematological screening revealed higher erythrocyte count in BGN Tg mice compared to their WT littermates (Fig. 2a) . In contrast, no significant difference was observed in white blood cell count (WT 9.9 ± 3.0 × 10 ; n = 15; n.s.). Complementing the increased erythrocyte number, BGN Tg mice also revealed elevated hematocrit value (Fig. 2b) and enhanced hemoglobin concentrations (Fig. 2c) . Analysis of the blood revealed no alteration in iron concentration (WT 19.7 ± 2.3 μmol/l vs. BGN Tg 21.2 ± 2.3 μmol/l; n = 15; n.s.) or transferrin saturation (WT 32.8 ± 3.3 % vs. BGN Tg 32.8 ± 3.2 %; n = 15; n.s.). However, total iron binding capacity (TIBC), a value that ordinarily correlates with transferrin concentration, was increased in BGN Tg mice (Fig. 2d) . Comparable effects were observed in male and female animals (data not shown), indicating that gender did not 
Altered spleen morphology and elevated splenic iron deposition in BGN
Tg mice
In the course of their lifetime in circulation, erythrocytes undergo membrane changes which make them more susceptible to phagocytosis by macrophages, also referred to as eryptosis [34] . It is well established that polycythemia results in increased eryptosis marked by altered spleen morphology and enhanced splenic iron deposition [35, 36] . Thus, we determined whether stable overexpression of soluble biglycan would affect the overall splenic architecture and iron deposition. Histologic analysis using periodic acid-Schiff staining of the spleen revealed in BGN Tg mice 2-fold enhancement of the red pulp (RP) area (Fig. 3a, b) , the major site for senescent erythrocyte degradation [34] . In contrast, the white pulp (WP) and marginal zone architectures were comparable in BGN Tg and WT mice (Fig. 3a) . Furthermore, quantification of the RP/WP area showed an enhancement of this ratio in the spleen of BGN Tg mice (WT 0.8 ± 0.5 vs. BGN Tg 2.9 ± 1.2; n = 6, P < 0.05). Additionally, Perls' Prussian blue staining revealed an increased splenic deposition of the Fe 3+ -storage complex hemosiderin in BGN Tg mice (Fig. 3c , indicated by black arrows and quantified in Fig. 3d ). These results demonstrate that the polycythemia in BGN Tg mice coincides with increased RP area and iron deposition in the spleen, likely due to the augmented eryptosis.
Increased Epo expression and HIF-2α levels in liver and kidneys of BGN Tg mice
A selective enhancement of erythrocytes in BGN Tg mice implied that chronic overexpression of soluble biglycan may cause the development of secondary polycythemia. To test this hypothesis, we determined Epo expression in BGN Tg mice. qRT-PCR analysis revealed a 1.6-and 2.3-fold induction of Epo mRNA expression in the liver and kidneys of BGN Tg compared to WT mice (Fig. 4a) . Furthermore, Epo protein levels as determined by a specific ELISA, were concurrently elevated in both parenchymal organs (Fig. 4b) and plasma (Fig. 4c) of BGN Tg mice. Importantly, this enhancement ( Fig. 4a-c) was associated with a 2-fold increase of HIF-2α protein levels in liver (WT 0.12 ± 0.03 vs. BGN Tg 0.26 ± 0.04; n = 3; P < 0.05) and kidneys (WT 0.30 ± 0.02 vs. BGN Tg 0.55 ± 0.10; n = 3; P < 0.05) of BGN Tg mice (Fig. 4d) . Higher HIF-2α protein abundance in liver and kidneys of mice overexpressing biglycan implicates involvement of this canonical transcription factor in biglycan-mediated effects on Epo synthesis. Interestingly, HIF-2α mRNA expression was not altered in liver (WT 1.00 ± 0.07 vs. BGN Tg 0.95 ± 0.38, n = 4, n.s.) or kidneys (WT 1.05 ± 0.45 vs. BGN Tg 0.94 ± 0.37; n = 4, n.s.) of BGN Tg mice compared to WT mice. We conclude that 
TLR2 is required for biglycan-mediated Epo induction and polycythemia
Next, we searched for a mechanism of action of soluble biglycan-evoked Epo/HIF-2α levels. Accordingly, we transiently overexpressed soluble biglycan in WT mice as described previously [25] [26] [27] . We found that the plasma levels of Epo were significantly higher in mice injected with hBGN pLIVE for three days vis-à-vis mice injected with empty vectors (Fig. 5a) . Concurrently, these mice displayed elevated HIF-2α protein level in liver (WT pLIVE 0.24 ± 0.01 vs. hBGN pLIVE 1.61 ± 0.14; n = 3; P < 0.05) and kidneys (WT pLIVE 0.14 ± 0.02 vs. hBGN pLIVE 0.66 ± 0.01; n = 3; P < 0.05) (Fig. 5b) as well as higher erythrocyte count (Fig. 5c) . Collectively, our findings provide evidence for a direct involvement of soluble biglycan in the enhancement of Epo concentration, HIF-2α protein abundance and erythrocytes number.
Furthermore, we identified the receptor involved in this process. To this end, we transiently transfected WT, Tlr2 
Tlr4
−/− and Tlr2 −/− /4-m mice (TLR-2-deficient mice carrying a functional mutation in the Tlr4 gene) with hBGN pLIVE. In WT and Tlr4 −/− mice, three days of biglycan transfection resulted in a marked overexpression of the Epo mRNA in the liver (Fig. 5d) and kidneys (Fig. 5e ). In contrast, there was no difference in liver (Fig. 5d) and kidneys (Fig. 5e ) of hBGN pLIVE transfected Tlr2 −/− and Tlr2
−/− /4-m mice. Thus, we provide robust genetic evidence that soluble biglycan directly stimulates the expression of Epo in the liver and kidneys by selectively interacting with TLR2.
Discussion
In this study we describe the generation of a mouse model stably overexpressing soluble human biglycan (BGN Tg ), which displays increased Epo expression and HIF-2α stabilization in liver and kidneys, associated with the development of polycythemia. BGN Tg mice overexpress human biglycan under an albumin promoter in the liver with subsequent secretion into the circulation and accumulation in various organs, here shown for the kidney. Although BGN Tg mice appear healthy, blood analysis revealed a hematological phenotype characterized by increased erythrocyte number, hemoglobin concentration, hematocrit values and TIBC, consistent with a clinical picture of secondary polycythemia. Further investigations revealed elevated Epo concentrations in liver, kidneys and the circulation of BGN Tg mice, coinciding with elevated erythrocyte counts, changes in the spleen structure and enhanced splenic iron deposition. In addition, BGN Tg mice displayed higher hepatic and renal concentrations of HIF-2α, the key transcription factor known to regulate Epo expression [8, 9] . Moreover, transient overexpression of soluble biglycan for 3 days induced Epo mRNA expression in an exclusively TLR2-dependent manner in both liver and kidneys. We therefore hypothesize that this biological axis might be directly linked to higher HIF-2α levels in both parenchymal organs, liver and kidney, as well as circulating Epo concentrations and erythrocyte numbers. Our current working model is graphically depicted in Fig. 6 .
Mice stably-transfected with human biglycan under the control of an albumin promoter displayed higher concentrations of biglycan in the circulation and organs that are equal to those found in experimental and human systemic disorders [25] [26] [27] 33] . Therefore, these transgenic mice provide a useful model to study consequences of a long-term exposure to soluble biglycan. In contrast, transient overexpression of soluble biglycan in mice deficient for various receptors or signaling molecules allows the in vivo identification of specific signaling pathways evoked by this proteoglycan, as shown here for TLR2. In our study we purposefully utilized the full-length human biglycan to allow a clear distinction between the endogenous murine and exogenous human product. We took advantage of a human-specific SacI restriction site that allowed us to verify its transgenic expression in BGN Tg livers. Lower intensity of murine biglycan expression band detected in BGN Tg livers (Fig. 1e) was not due to suppressed endogenous biglycan, but was probably caused by reduced primer availability, as human (bp 573-1001) and murine biglycan (bp 585-1013) sequences show 90 % homology in their cDNA. By using primers distinguishing endogenous mouse from human biglycan, we detected equal expression of mouse biglycan in livers from WT and BGN Tg mice. BGN Tg mice showed a clinical picture consistent with secondary erythrocytosis, which generally develops from excessive production of Epo secondary to systemic hypoxia, due to severe pulmonary disease, heart anomalies resulting in rightto-left shunting with blood bypassing the lungs, or high altitude syndrome. In such cases, the erythrocytosis is considered an appropriate compensatory response. If Epo production increases without systemic hypoxia, then the response is inappropriate. For example, there are several neuroendocrine tumors that have the ability to synthesize and release Epo into the blood stream and induce polycythemia. Although we have not measured the oxygen concentration in our mice, it is highly unlikely that our BGN Tg mice are chronically hypoxic, given the fact that they appear normal, have normal weight and reproduce as WT animals (see below). Histologic examination of the spleen showed an increase in the zone occupied by the red pulp suggesting extramedullary erythropoiesis. In addition, we observed a large increase in iron deposition in the red pulp, indicating increased uptake and catabolism of erythrocytes. During phagocytosis and degradation of erythrocytes, iron released from hemoglobin is bound by the iron storage complex hemosiderin [36] . These findings in the spleen are in full agreement with previously-published studies in mice affected by polycythemia [35, 37] . Both livers and kidneys of the BGN Tg mice showed overexpression of Epo mRNA and protein, with consequently high levels of circulating Epo and secondary erythocytosis. Notably, we could validate these chronic changes using a transient transgenic mouse model [25] [26] [27] [28] , clearly indicating direct effects of soluble biglycan on Epo production and development of polycythemia. It was shown previously, that mice stably overexpressing human Epo develop secondary polycythemia [38, 39] . However, to our knowledge, this is the first report that a secreted matrix component is capable of triggering Epo expression and causing polycythemia.
It is well established that Epo expression is mainly regulated by HIF-2α [8] . Mice stably-and transiently-transfected with biglycan displayed higher HIF-2α protein abundance in liver and kidneys. As mRNA expression of HIF-2α was not induced in BGN Tg mice we hypothesize that biglycan could cause HIF-2α stabilization [10, 13] . Stabilization of HIF-1α has been demonstrated to depend on the phosphorylation of Erk1/2 and p38 [40, 41] . Notably, biglycan regulates Epo expression by signaling via TLR2 and we have previously shown that this biglycan/TLR2 interactions activates both Erk1/2 and p38 pathways [22] . Thus, it is conceivable that a regulatory mechanism of biglycan-dependent HIF-2α stabilization might involve Erk1/2 and p38. Furthermore, ROS are potent stabilizers of HIF-2α protein [42] . Thus, biglycan by triggering ROS production [24] could stabilize HIF-2α. We have previously shown that decorin, a structurally-related proteoglycan [16] , inhibits tumor angiogenesis by downregulating the mRNA and protein expression of constitutively-active HIF-1α in breast carcinoma cells [43] . Furthermore, treatment of retinal pigment epithelial cells with decorin effectively reduced the expression of HIF-1α under hypoxic conditions [44] . However in contrast to biglycan, decorin was involved in transcriptional regulation of HIF-1α and not in protein stabilization.
There is increasing evidence for oxygen-independent regulation of HIF-1α [15, 45] . In contrast, regulation of HIF-2α appears to be primarily controlled by the reduction in oxygen tension and by general hypoxic environmental conditions [46] . As BGN Tg mice had normal growth, weight, lifespan and fertility and displayed no obvious clinical symptoms of chronic hypoxia, we postulate that biglycan-mediated regulation of HIF-2α and Epo occurs via a hypoxia-independent pathway.
Mechanistically, by transiently overexpressing biglycan in mice with genetic deletion of various TLRs, we demonstrated that biglycan-induced Epo mRNA expression in liver and kidneys is solely dependent on TLR2. The pro-inflammatory effects of biglycan are generally induced by a crosstalk between TLR2 and TLR4 [22, [25] [26] [27] . However, we have recently discovered an ability of biglycan to tightly regulate the inflammatory response via selective interaction with only one TLR [28] . Not much is known about the involvement of TLRs in Epo production. Up-to-date, only the involvement of TLR4 in erythropoiesis was proven in a model of Salmonella infection [47] . Thus biglycan signaling exclusively via TLR2 represents a new regulatory mechanism of Epo production and hence erythropoiesis.
The clinical relevance of our data is underlined by the finding that systemic biglycan overexpression effects red blood cell formation. As such, the use of biglycan as therapeutic protein, e.g. for amelioration of mild muscular dystrophy [48] should be approached cautiously. By contrast, patients with thalassemia suffering from anemia, iron overload and accelerated bone loss [49] might benefit from the numerous and newly identified functions of biglycan.
In summary, the novelty of our findings is three-fold: 1) This is the first report depicting a matrix component in its soluble form as a crucial trigger of Epo synthesis and inducer of secondary polycythemia. 2) We identify TLR2 as the key signaling receptor driving biglycandependent Epo synthesis. 3) We propose a new mechanism of posttranscriptional enhancement of HIF-2α protein by biglycan that is presumably an oxygenindependent HIF-2α stabilization. Although the clinical relevance of these findings is not yet known, we predict that enhanced levels of soluble biglycan might increase the clinical risk of thrombosis, cardiac infarction and stroke [1, 2] .
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